Tempus gets up to $9.5M to test Olivia as autonomous heart-care AI
Eric Lefkofsky's Tempus will develop and validate a heart-failure agent under an FDA-engaged federal program, though its authorization path and treatment authority remain unsettled.
By RuntimeWire Staff · Published
Primary source: Tempus AI on X
Why it matters
Tempus now has federal funding to develop and prospectively test an autonomous heart-failure agent. The study could produce evidence for clinical and regulatory review, but no authorization, treatment authority or patient benefit has been established.
Eric Lefkofsky (@lefkofsky) has secured up to $9.5 million in federal support for Tempus to develop an AI agent intended to manage parts of heart-failure care, pushing his decade-old precision-medicine business beyond diagnostics and alerts toward clinical action.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.